Ricardo Commissioned to Define a Single Harmonised European Life Cycle Assessment Standard for Zero Emission Vehicles and Batteries
15.2.2023 03:01:00 EET | Business Wire | Press release
Ricardo, a global strategic environmental and engineering consulting company, has commenced a European Union-funded project to develop a baseline for a European-wide commonly accepted and applied single life cycle assessment (LCA) approach for zero emission vehicles (ZEV) and batteries based on evidence and real-world data. This initiative is a Coordination and Support Action supported under the Horizon Europe Framework Programme and has also received funding from UK Research and Innovation (UKRI).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230214005551/en/
Electric car and truck charging (Photo: Business Wire)
Currently, there is no agreed European or international standard on vehicle life cycle assessment, although there are a number of standards in draft or being developed for electric vehicle (EV) batteries. Defining a single, harmonised life cycle assessment approach for vehicles and batteries is key to providing transparency and comparability of impacts from these products. This will help to achieve Green Deal targets, making Europe the first digitally enabled circular, climate-neutral and sustainable economy. Harmonised standards will facilitate industry, mobility providers and planners to develop sustainable road transport products that are optimised to combat climate change. Ricardo is on the core team of the collaborative TranSensus LCA consortium – jointly coordinated by the Fraunhofer Institute for Structural Durability and System Reliability LBF and the Fraunhofer-Institution of Surface Engineering and Thin Films IST– which comprises 44 stakeholders from industry and research along the full value chain of zero emission vehicles and batteries including: research institutions, vehicle and battery manufacturers, the supply industry, energy providers and recyclers.
Nikolas Hill, Head of Vehicle Technologies and Fuels in Ricardo’s Sustainable Transport team said: “The major report on life cycle impacts of road vehicles that Ricardo undertook for the European Commission in 2020 highlighted the importance of life cycle assessment in sustainable product and business development, but also the challenges for its application. In particular, efforts fully to use and realise the benefits from life cycle assessment approaches by the transport sector are being hampered because there is not an official European standard for vehicle LCA. This is largely because of a lack of a consistent, fair framework or harmonised methodology, plus limitations in accessing and managing real-world data and applying consistent modelling. Through our work with our industry and research partners on this project, Ricardo policy, strategy and technology experts will help to deliver a standard, trustworthy and consistent assessment of full vehicular environmental footprints, to support organisations across the transport value chain progress their objective of achieving climate neutrality.”
Ricardo’s 2020 report for the European Commission, DG Climate Action: Determining the environmental impacts of conventionally and alternatively fuelled vehicles through LCA was the broadest and most comprehensive study of its kind to date. The report assessed the life cycle impacts of 65 different European light- and heavy-duty vehicle types and powertrain combinations. It considered the production of 60 fuel chains for conventional and alternative fuels as well as 14 different forms of electricity generation, the impacts of vehicle (and battery) manufacturing, and vehicle use and maintenance including different ‘end of life’ scenarios. The report also highlighted the positive impact of existing European Union policy in directly supporting the move to a more circular economy and the initiatives aimed at developing a sustainable value chain for hybrid and fully electric vehicles and their batteries in driving down industrial emissions and improving resource efficiency.
Ends
Notes to editors:
TranSensus LCA is funded by the European Union under the Grant Agreement #101056715. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or CINEA. Neither the European Union nor the granting authority can be held responsible for them.
About Ricardo
Ricardo plc is a global strategic, environmental, and engineering consulting company, listed on the London Stock Exchange. With over 100 years of engineering excellence and employing close to 3,000 employees in more than 20 countries, we provide exceptional levels of expertise in delivering leading-edge and innovative cross-sector sustainable products and solutions. Every day, we enable our customers to solve the most complex and dynamic challenges to help achieve a safe and sustainable world. Visit www.ricardo.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230214005551/en/
Contact information
Kathryn Bellamy
Group Senior Communications Manager
Ricardo plc
Email: kathryn.bellamy@ricardo.com
Telephone: +44(0)7921 941824
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 20263.10.2026 17:50:00 EEST | Press release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1b C-800-01 trial. The study evaluated botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), Agenus’ anti-PD-1 antibody. The results, including three-year survival and outcomes by sensitivity to platinum-based chemotherapy and by prior treatment, were presented at the 2026 International Gynecologic Cancer Society (IGCS) Annual Global Meeting in Montréal, Canada. Among patients evaluable for efficacy, three-year overall survival was 48% (n=35), unchanged from the two-year estimate, suggesting durable clinical benefit in this population. Responses and long-term survival were observed in both platinum-sensitive and platinum-resistant or refractory disease. At the last follow-up, 25% of patients who received at least one dose of treatment (11 of 44) were alive
emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer2.10.2026 18:12:00 EEST | Press release
emnify, a global leader in IoT connectivity, today announced the appointments of Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001902751/en/ emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer The appointments follow the recent naming of Kenneth De Spiegeleire as Chief Executive Officer and Frank Stoecker as Executive Chairman of the Board. Together, these leadership changes strengthen emnify financial, operational, and commercial capabilities as the company enters its next phase of international growth. “We have proven momentum. Our ambition is to now turn it into global category leadership,” said Kenneth De Spiegeleire, CEO of emnify. “That requires sharper focus, disciplined execution, and the right capabilities in the right seats. Sacha brings financial lead
Tacton Appoints Former IFS Executive Merlin Knott as Chief Commercial Officer to Accelerate Global Growth and Scale Beyond CPQ2.10.2026 16:00:00 EEST | Press release
Tacton, a global leader in Configure, Price, Quote (CPQ) software and configuration solutions for manufacturers of complex products, today announced the appointment of Merlin Knott as Chief Commercial Officer (CCO). In this role, Knott will lead Tacton’s global commercial organization, including marketing, sales, and pre-sales, aligning the teams responsible for bringing Tacton’s solutions to market, and driving value to its customers and partners globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261002794882/en/ Merlin Knott, Chief Commercial Officer, Tacton Knott joins Tacton with decades of experience building and scaling commercial organizations across the enterprise software industry. Most recently, he held senior leadership roles at IFS, the world’s leading provider of Industrial AI software, where he led global partner and channel operations before becoming President of the company’s Enterprise Service Manageme
EDW Presents 2026 Data Quality Award to Repeat Winner Domivest2.10.2026 16:00:00 EEST | Press release
European DataWarehouse (EDW) presented its fifth annual Data Quality Award at the 2026 TSI Congress in Berlin. This year, EDW's Best Data Quality – Deal of the Year (2026) award was presented to Domivest B.V. for its transaction Domi 2023-1 B.V., recognising the firm's outstanding commitment to accurate, complete, and consistent reporting. The award is based on EDW's proprietary data quality scoring methodology, which evaluates transactions against thousands of validation rules and checks. Data quality excellence is not a one-off achievement. The fact that the same issuers continue to rank among the top performers year after year demonstrates that superior data quality is the result of sustained commitment, robust processes, and ongoing investment. "Receiving the Data Quality Award for a second time means a great deal to us. Transparent, accurate loan-level data is key to investor trust in our transactions, and we are grateful to European DataWarehouse for recognising the work our trea
ILiAD Biotechnologies Expands BPZE1 Public Health and Commercial Potential with Publication of Pediatric Phase 2b Study in The Lancet Infectious Diseases2.10.2026 15:00:00 EEST | Press release
ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the publication of results from its Phase 2b SUPER (Stand Up to Pertussis) clinical trial in The Lancet Infectious Diseases. This randomized, double blind, placebo- and active-comparator-controlled trial demonstrated that BPZE1, a live attenuated intranasal pertussis vaccine, induced robust nasal mucosal immune responses in healthy children aged 6 through 17 years (LINK). The study demonstrated that a single intranasal dose of BPZE1 induced nasal mucosal immune responses against all Bordetella pertussis antigens tested and was well tolerated, both when administered alone and when co-administered with a tetanus-diphtheria-acellular pertussis (Tdap) booster vaccine. The multi-center Phase 2b trial enrolled 366 participants across 16 sites in the United Kingdom, Australia, and Costa Rica and included participants
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
